Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Analysis of the Predictive Value of Immune Cell Using Single-cell Sequencing on the Outcome of Locally Advanced Cervical Cancer Treated by Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor

NCT06378840 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT06378840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06378840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Analysis of the Predictive Value of Immune Cell Using Single-cell Sequencing on the Outcome of Locally Advanced Cervical Cancer Treated by Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor
Lead sponsor
RenJi Hospital
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2022
Completion date
December 30, 2024
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

concurrent chemoradiotherapy, immunotherapy, locally advanced cervical carcinoma